## Lab Band



## THE PROBLEM

Periodic monitorization done through blood analysis delivers punctual information but not in a continuous manner.

Patients treated in ICU's and hospitalizations have a catheter for blood draws which causes vascular damages such as: hematomas, thrombosis (between 4% and 15%) and infections (between 13% and 50%). Chronic patients with heart and respiratory diseases as well as diabetes need to be monitored periodically.

MILESTONES

**Proof of Concept** 

Analytic Validation

**Patent Protection** 

**Clinical Validation** 

CE Mark/ Market Launch

Founded 2016

2016

2017

2018

2019

2019-2020

THE SOLUTION

Non-invasive clinical monitoring systems through chemical microsensors and miniaturized biosensors.

Our device is monitoring the patient in a continuous way using the patient's sweat instead of blood, avoiding possible catheter-related complications and delivering much more data to the medical team, providing the necessary information to enable personalized medicine.

## THE PRODUCT

The first non-invasive monitoring solution measuring chemical parameters (lactate, pH, glucose and CO2) present in sweat using miniaturized biosensors.

- Improves life conditions of chronic patients.
- Minimizes hospitalization situations for chronic patients.
- Measures relevant biomarkers anytime and anywhere.
- Detects and controls the clinical impairment.

POTENTIAL MARKET	KEY METRICS	
World population affected by NCD's:	155€	Price reader + sensor
Diabetes 422M Respiratory 449M	12%	Potential Penetration Rate
Cardiovascular 423M	15M €	Projected Gross Annual Revenue by 2020
FUNDING GOALS	1,8B € /year	Potential US Market
a 43% R+D + Validation 35% Marketing 1,8M € a 15% Design	6M €	Current Valuation in the Market













Xavi Muñoz CEO



Elisabet del Valle CCO



Ferran Rosés CMO



Josep Cardona Innovation Director









Agència de Qualitat i Avaluació Sanitàries de Catalunya

